Please read and agree to the terms and conditions of this site.
@xconomy.com 3 months ago
FDA Panel Vote Weighs in Favor of Alkermes Psyche Drug, With Caveats
@xconomy.com 4 months ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com 4 months ago
Grail Files to Go Public; 5 More Life Science Firms Join the IPO Queue
@xconomy.com 4 months ago
Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More
@xconomy.com 5 months ago
AbbVie Exits Editas Alliance, Pruning Another Genetic Medicines Pact
@xconomy.com 10 months ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com 12 months ago
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More
@xconomy.com 1 year ago
Allergan Wins FDA Nod for First Migraine Pill in New Class of Medicines
@xconomy.com 1 year ago
Disc Medicine Launches With $50M to Advance New Anemia Treatments
@xconomy.com 1 year ago
Bio Roundup: Cholesterol Check, J&J’s Opioid Hit, AbbVie’s Flop & More
@xconomy.com 1 year ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com 1 year ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@techcrunch.com 1 year ago
What top VCs look for in women’s fertility startups
@xconomy.com 1 year ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@geekwire.com 1 year ago
Seattle startup Rodeo Therapeutics raises more cash for regenerative medicine treatments
@xconomy.com 1 year ago
Pharma CEOs to Senate: We Will Lower Drug Prices if Rebates Go Away
@xconomy.com 1 year ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com 2 years ago
Bio Roundup: $74B for Celgene, Two CAR-T Tales, Ready for SF & More
@xconomy.com 2 years ago
Acorda Gets FDA Nod For New Parkinson’s Drug, But Rival Looms
@xconomy.com 2 years ago
ASH 2018: A Guide to the Latest for Blood-Borne Cancers and More
@xconomy.com 2 years ago
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More